🇺🇸 Aldara (Imiquimod) in United States

22 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 22

Most-reported reactions

1. Haemoglobin Decreased — 3 reports (13.64%)
2. Platelet Count Decreased — 3 reports (13.64%)
3. Application Site Erythema — 2 reports (9.09%)
4. Application Site Pain — 2 reports (9.09%)
5. Dehydration — 2 reports (9.09%)
6. Drug Administered At Inappropriate Site — 2 reports (9.09%)
7. Inappropriate Schedule Of Drug Administration — 2 reports (9.09%)
8. Palpitations — 2 reports (9.09%)
9. Pyrexia — 2 reports (9.09%)
10. Vomiting — 2 reports (9.09%)

Source database →

Frequently asked questions

Is Aldara (Imiquimod) approved in United States?

Aldara (Imiquimod) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Aldara (Imiquimod) in United States?

MEDA Pharma GmbH & Co. KG is the originator. The local marketing authorisation holder may differ — check the official source linked above.